



NEWS RELEASE

# Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

2024-09-06

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- **Evolus, Inc.** (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024.

The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. The Nasdaq closing bell ceremony will take place at the Nasdaq MarketSite in Times Square, New York City. David Moatazedi, Evolus' President and Chief Executive Officer, will preside over the ceremony, joined by members of the company's leadership team and guests.

Evolus' President and Chief Executive Officer, David Moatazedi, commented, "We are honored to have the opportunity to commemorate our success as a publicly traded company following our five-year anniversary this past May and recent investor day on September 12th in New York City. Our accomplishments would not have been possible without the dedication and support of our exceptional team, partners, and customers. Their unwavering commitment has fueled our evolution from a single-product aesthetics company to a multi-product performance beauty innovator. Today, we celebrate their collective efforts and the strong foundation we have built for continued growth, consumer satisfaction, and value creation for our shareholders."

The live broadcast of the Nasdaq Closing Bell ceremony will begin at 3:45 p.m. Eastern Time on Friday, September 13, 2024. To view the broadcast, visit: <https://www.nasdaq.com/marketsite/bell-ringing-ceremony> .

Management will also take part in a Behind the Bell interview from the Nasdaq MarketSite before the closing bell ceremony, which will be available **here** once published.

## About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau<sup>®</sup> (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure<sup>™</sup> technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse<sup>™</sup>, and the exclusive distributor in Europe of Estyme<sup>®</sup>, a line of unique dermal fillers currently in late-stage development. Visit us at [www.evolus.com](http://www.evolus.com), and follow us on [LinkedIn](#), [X](#), [Instagram](#) or [Facebook](#).

Jeuveau<sup>®</sup> and Nuceiva<sup>®</sup>, are registered trademarks and Evolysse<sup>™</sup> is a trademark of Evolus, Inc.

Hi-Pure<sup>™</sup> is a trademark of Daewoong Pharmaceutical Co, Ltd.

Estyme<sup>®</sup> is a trademark of Symatase Aesthetics S.A.S.

### Investors:

Nareg Sagharian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: [ir@evolus.com](mailto:ir@evolus.com)

### Media:

Email: [media@evolus.com](mailto:media@evolus.com)

Source: Evolus